Advertisement

Clinical and Translational Oncology

, Volume 14, Issue 5, pp 350–355 | Cite as

Episcleral brachytherapy for uveal melanoma: analysis of 136 cases

  • Ciro García-ÁlvarezEmail author
  • María Antonia Saornil
  • Francisco López-Lara
  • Ana Almaraz
  • María Fe Muñoz
  • Jesús Frutos-Baraja
  • Yerena Muiños
Research Articles

Abstract

Purpose

To assess the results of I-125 episcleral brachytherapy (EB) in uveal melanoma: tumour control, visual acuity (VA), eye preservation and survival.

Patients

Prospective and consecutive study of patients with a diagnosis of uveal melanoma at the Ocular Oncology Unit in the Valladolid University Teaching Hospital treated with EB between September 1997 and June 2008. Ocular examination and extraocular and systemic extension data were registered in a database at the time of the diagnosis and during the follow-up.

Results

Among a total of 310 patients diagnosed between September 1997 and June 2008, 136 were treated with EB (mean age, 58.3). Mean follow-up was 55.3 months. As for tumour type, 66.9% were nodular and 39% mushroom shaped. With respect to size, 80.9% were medium, 7.4% small and 11.8% large. After 4.6 years of follow-up, tumours were controlled in 97.1%, with a 55.1% reduction in mean height; only 2.9% of patients showed recurrence. VA was maintained in 16.2% of patients and 17.6% showed an increase; 33% had retinopathy and 14.6% optic neuropathy. Only 5.1% of patients underwent enucleation due to complications and there has been 1 melanoma-related death to date.

Conclusions

I-125 EB is effective in tumour control, allowing preservation of the eye and useful visual function for the majority of patients.

Keywords

Intraocular tumours Uveal melanoma Episcleral brachytherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Singh A, Topham A (2003) Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology 110:956–961PubMedCrossRefGoogle Scholar
  2. 2.
    Diener-West M, Earle JD, Fine SL et al; Collaborative Ocular Melanoma Study Group (2001) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 119:969–982PubMedGoogle Scholar
  3. 3.
    Augsburger JJ, Schneider S, Freyre J, Brady LW (1999) Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol 237:558–567PubMedCrossRefGoogle Scholar
  4. 4.
    Bell JB, Wilson MD (2004) Choroidal melanoma: natural history and management options. Cancer Control 11: 296–303PubMedGoogle Scholar
  5. 5.
    COMS (1998) The Collaborative Ocular Melanoma Study (COMS) randomized trial of preenucleation radiation of large choroidal melanoma II: initial mortality findings. COMS Report No. 10. Am J Ophthalmol 125:779–796CrossRefGoogle Scholar
  6. 6.
    Finger PT (1997) Radiation therapy for choroidal melanoma. Surv Ophthalmol 42:215–232PubMedCrossRefGoogle Scholar
  7. 7.
    Wilson MW, Hungerford JL (1999) Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology 106:1579–1587PubMedCrossRefGoogle Scholar
  8. 8.
    Nag S, Quivey JM, Earle JD et al; American Brachytherapy Society (2003) The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 56:544–555PubMedCrossRefGoogle Scholar
  9. 9.
    Finger PT (1997) Radiation therapy for choroidal melanoma. Surv Ophthalmol 42:215–232. ReviewPubMedCrossRefGoogle Scholar
  10. 10.
    Saornil MA, Fisher MR, Campbell RJ et al (1997) Histopathologic study of eyes after iodine I 125 episcleral plaque irradiation for uveal melanoma. Arch Ophthalmol 115:1395–1400PubMedCrossRefGoogle Scholar
  11. 11.
    Damato B (2004) Developments in the management of uveal melanoma. Clin Experiment Ophthalmol 32:639–647. ReviewPubMedCrossRefGoogle Scholar
  12. 12.
    Margo CE (2004) The collaborative ocular melanoma study: an overview. Cancer Control 11:304–309PubMedGoogle Scholar
  13. 13.
    Bell DJ, Wilson MW (2004) Choroidal melanoma: natural history and management options. Cancer Control 11:296–303PubMedGoogle Scholar
  14. 14.
    Augsburger JJ, Correa ZM, Freire J, Brady LW (1998) Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 105:1670–1678PubMedCrossRefGoogle Scholar
  15. 15.
    Shields CL, Shields JA, Cater J et al (2000) Plaque radiotherapy for uveal melanoma: longterm visual outcome in 1106 consecutive patients. Arch Ophthalmol 118:1219–1228PubMedGoogle Scholar
  16. 16.
    Sobin LH, Wittekind Ch (2002) UICC: TNM classification of malignant tumours, 6th edn. Wiley, New YorkGoogle Scholar
  17. 17.
    Caminal Mitjana JM, Quintana Casany M, Pera Fabregas J et al (2002) Results of Iodine-125 radiotherapy in the treatment of uveal melanoma. Arch Soc Esp Oftalmol 77:29–38PubMedGoogle Scholar
  18. 18.
    COMS (2002) The Collaborative Ocular Melanoma Study (COMS) randomized trial of iodine 125 brachytherapy for choroidal melanoma IV: local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19. Ophthalmology 109:2197–2206CrossRefGoogle Scholar
  19. 19.
    Valcarcel F, Valverde S, Cardenes H et al (1994) Episcleral iridium-192 wire therapy for choroidal melanomas. Int J Radiat Oncol Biol Phys 30:1091–1097PubMedCrossRefGoogle Scholar
  20. 20.
    Damato B, Patel I, Campbell IR et al (2005) Related articles, local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 63:385–391PubMedCrossRefGoogle Scholar
  21. 21.
    Correa R, Pera J, Gomez J et al (2009) 125 I plaque brachytherapy in the treatment of choroidal melanoma: a single institution experience in Spain. Brachytherapy 8:290–296PubMedCrossRefGoogle Scholar
  22. 22.
    COMS (2001) The Collaborative Ocular Melanoma Study (COMS) randomized trial of iodine 125 brachytherapy for medium choroidal melanoma I: visual acuity after 3 years. COMS Report No. 16. Ophthalmology 108:348–366CrossRefGoogle Scholar

Copyright information

© Feseo 2012

Authors and Affiliations

  • Ciro García-Álvarez
    • 1
    Email author
  • María Antonia Saornil
    • 1
  • Francisco López-Lara
    • 1
  • Ana Almaraz
    • 2
  • María Fe Muñoz
    • 3
  • Jesús Frutos-Baraja
    • 1
  • Yerena Muiños
    • 4
  1. 1.Intraocular Tumors UnitHospital Clínico Universitario de ValladolidValladolidSpain
  2. 2.Departamento de Medicina Preventiva y Salud Pública Facultad de MedicinaUniversidad de ValladolidValladolidSpain
  3. 3.Statistics UnitHospital Clínico Universitario de ValladolidValladolidSpain
  4. 4.Policlínica Vigo SAVigo, PontevedraSpain

Personalised recommendations